Advanced Pharmacology Practice Exam 2026
Questions with Answers & Rationales
*A general NP/graduate-level pharmacology review ΓÇö not affiliated with or copied from any specific
university's proctored exam.*
**Format:** Multiple choice, 4 options each. Answer key with brief rationale follows each question.
---
## Section 1: Pharmacokinetics & Pharmacodynamics (Q1ΓÇô15)
**1.** A drug with a large volume of distribution (Vd) most likely:
A) Stays mainly in the blood
B) Is highly protein-bound only
C) Distributes extensively into tissues
D) Is rapidly excreted unchanged
**Answer: C** ΓÇö A large Vd indicates the drug leaves the plasma and concentrates in tissues rather than
staying in the vascular compartment.
**2.** Which route of administration avoids first-pass hepatic metabolism?
A) Oral
B) Sublingual
C) Rectal (upper)
D) Enteral feeding tube
**Answer: B** ΓÇö Sublingual absorption enters systemic circulation directly, bypassing the portal system
and first-pass metabolism.
**3.** A drug that is a CYP3A4 inhibitor will most likely:
A) Decrease levels of co-administered CYP3A4 substrates
B) Increase levels of co-administered CYP3A4 substrates
C) Have no effect on other drugs
D) Only affect renally cleared drugs
**Answer: B** ΓÇö Inhibiting the enzyme responsible for metabolizing a substrate drug slows its clearance,
raising serum levels.
**4.** Zero-order kinetics means:
A) A constant fraction of drug is eliminated per unit time
B) A constant amount of drug is eliminated per unit time
C) Elimination rate depends on dose
D) Half-life is constant regardless of dose
**Answer: B** ΓÇö Zero-order elimination proceeds at a fixed amount/time (saturated enzyme systems),
unlike first-order (constant fraction).
**5.** Which patient factor most affects loading dose calculations?
,A) Renal function
B) Hepatic function
C) Volume of distribution
D) Drug half-life
**Answer: C** — Loading dose = (Vd × target concentration), so Vd is the primary determinant.
**6.** Highly protein-bound drugs are of greatest concern in patients with:
A) Hyperalbuminemia
B) Hypoalbuminemia
C) Elevated hematocrit
D) Normal renal function
**Answer: B** ΓÇö Low albumin means more free (active/unbound) drug, increasing toxicity risk for highly
protein-bound medications.
**7.** A drug's therapeutic index (TI) is defined as:
A) ED50/LD50
B) LD50/ED50
C) Peak/trough ratio
D) Half-life/dosing interval
**Answer: B** ΓÇö TI = LD50/ED50 (or TD50/ED50); a low TI means a narrow margin between toxic and
effective doses.
**8.** Which of the following drugs has a narrow therapeutic index requiring routine monitoring?
A) Amoxicillin
B) Warfarin
C) Acetaminophen (standard dosing)
D) Loratadine
**Answer: B** ΓÇö Warfarin has a narrow therapeutic index and requires INR monitoring.
**9.** First-order elimination kinetics means:
A) A constant amount is eliminated per unit time
B) A constant percentage/fraction is eliminated per unit time
C) Elimination is independent of concentration
D) Half-life increases with higher doses
**Answer: B** ΓÇö Most drugs follow first-order kinetics: elimination rate is proportional to drug
concentration.
**10.** Which enzyme system is responsible for the majority of phase I drug metabolism?
A) Glucuronyl transferase
B) Cytochrome P450
C) Acetyltransferase
D) Sulfotransferase
**Answer: B** ΓÇö CYP450 enzymes (oxidation, reduction, hydrolysis) carry out most phase I reactions.
, **11.** A pharmacodynamic drug interaction occurs when:
A) One drug changes the absorption of another
B) Two drugs have additive, synergistic, or antagonistic effects at the receptor/tissue level
C) One drug alters hepatic enzyme activity
D) One drug changes urinary pH
**Answer: B** ΓÇö Pharmacodynamic interactions involve combined physiologic effects, not changes in
serum levels (which is pharmacokinetic).
**12.** Which statement about half-life is correct?
A) It takes 1 half-life to reach steady state
B) It takes approximately 4ΓÇô5 half-lives to reach steady state
C) Half-life is unrelated to dosing interval
D) Half-life only applies to IV drugs
**Answer: B** ΓÇö Steady state is reached after roughly 4ΓÇô5 half-lives with consistent dosing.
**13.** A prodrug is best described as:
A) A drug that is active in its administered form
B) An inactive compound converted to an active metabolite in the body
C) A drug with no metabolism
D) A drug only given IV
**Answer: B** ΓÇö Prodrugs require metabolic conversion (often hepatic) to become pharmacologically
active.
**14.** Renal drug clearance is most impaired in a patient with:
A) eGFR 90 mL/min
B) eGFR 15 mL/min
C) eGFR 70 mL/min
D) Normal creatinine
**Answer: B** ΓÇö An eGFR of 15 reflects severe renal impairment (stage 4ΓÇô5 CKD), significantly reducing
clearance of renally eliminated drugs.
**15.** Which best describes an agonist-antagonist (partial agonist) drug?
A) Full activation of the receptor
B) No receptor binding at all
C) Binds the receptor but produces a submaximal response
D) Always increases the effect of a full agonist
**Answer: C** ΓÇö Partial agonists bind and activate receptors but with lower maximal efficacy than full
agonists, and can blunt effects when combined with a full agonist.
---
## Section 2: Cardiovascular Pharmacology (Q16ΓÇô30)
**16.** A patient on lisinopril develops a dry, persistent cough. The mechanism is:
A) Direct bronchospasm
Questions with Answers & Rationales
*A general NP/graduate-level pharmacology review ΓÇö not affiliated with or copied from any specific
university's proctored exam.*
**Format:** Multiple choice, 4 options each. Answer key with brief rationale follows each question.
---
## Section 1: Pharmacokinetics & Pharmacodynamics (Q1ΓÇô15)
**1.** A drug with a large volume of distribution (Vd) most likely:
A) Stays mainly in the blood
B) Is highly protein-bound only
C) Distributes extensively into tissues
D) Is rapidly excreted unchanged
**Answer: C** ΓÇö A large Vd indicates the drug leaves the plasma and concentrates in tissues rather than
staying in the vascular compartment.
**2.** Which route of administration avoids first-pass hepatic metabolism?
A) Oral
B) Sublingual
C) Rectal (upper)
D) Enteral feeding tube
**Answer: B** ΓÇö Sublingual absorption enters systemic circulation directly, bypassing the portal system
and first-pass metabolism.
**3.** A drug that is a CYP3A4 inhibitor will most likely:
A) Decrease levels of co-administered CYP3A4 substrates
B) Increase levels of co-administered CYP3A4 substrates
C) Have no effect on other drugs
D) Only affect renally cleared drugs
**Answer: B** ΓÇö Inhibiting the enzyme responsible for metabolizing a substrate drug slows its clearance,
raising serum levels.
**4.** Zero-order kinetics means:
A) A constant fraction of drug is eliminated per unit time
B) A constant amount of drug is eliminated per unit time
C) Elimination rate depends on dose
D) Half-life is constant regardless of dose
**Answer: B** ΓÇö Zero-order elimination proceeds at a fixed amount/time (saturated enzyme systems),
unlike first-order (constant fraction).
**5.** Which patient factor most affects loading dose calculations?
,A) Renal function
B) Hepatic function
C) Volume of distribution
D) Drug half-life
**Answer: C** — Loading dose = (Vd × target concentration), so Vd is the primary determinant.
**6.** Highly protein-bound drugs are of greatest concern in patients with:
A) Hyperalbuminemia
B) Hypoalbuminemia
C) Elevated hematocrit
D) Normal renal function
**Answer: B** ΓÇö Low albumin means more free (active/unbound) drug, increasing toxicity risk for highly
protein-bound medications.
**7.** A drug's therapeutic index (TI) is defined as:
A) ED50/LD50
B) LD50/ED50
C) Peak/trough ratio
D) Half-life/dosing interval
**Answer: B** ΓÇö TI = LD50/ED50 (or TD50/ED50); a low TI means a narrow margin between toxic and
effective doses.
**8.** Which of the following drugs has a narrow therapeutic index requiring routine monitoring?
A) Amoxicillin
B) Warfarin
C) Acetaminophen (standard dosing)
D) Loratadine
**Answer: B** ΓÇö Warfarin has a narrow therapeutic index and requires INR monitoring.
**9.** First-order elimination kinetics means:
A) A constant amount is eliminated per unit time
B) A constant percentage/fraction is eliminated per unit time
C) Elimination is independent of concentration
D) Half-life increases with higher doses
**Answer: B** ΓÇö Most drugs follow first-order kinetics: elimination rate is proportional to drug
concentration.
**10.** Which enzyme system is responsible for the majority of phase I drug metabolism?
A) Glucuronyl transferase
B) Cytochrome P450
C) Acetyltransferase
D) Sulfotransferase
**Answer: B** ΓÇö CYP450 enzymes (oxidation, reduction, hydrolysis) carry out most phase I reactions.
, **11.** A pharmacodynamic drug interaction occurs when:
A) One drug changes the absorption of another
B) Two drugs have additive, synergistic, or antagonistic effects at the receptor/tissue level
C) One drug alters hepatic enzyme activity
D) One drug changes urinary pH
**Answer: B** ΓÇö Pharmacodynamic interactions involve combined physiologic effects, not changes in
serum levels (which is pharmacokinetic).
**12.** Which statement about half-life is correct?
A) It takes 1 half-life to reach steady state
B) It takes approximately 4ΓÇô5 half-lives to reach steady state
C) Half-life is unrelated to dosing interval
D) Half-life only applies to IV drugs
**Answer: B** ΓÇö Steady state is reached after roughly 4ΓÇô5 half-lives with consistent dosing.
**13.** A prodrug is best described as:
A) A drug that is active in its administered form
B) An inactive compound converted to an active metabolite in the body
C) A drug with no metabolism
D) A drug only given IV
**Answer: B** ΓÇö Prodrugs require metabolic conversion (often hepatic) to become pharmacologically
active.
**14.** Renal drug clearance is most impaired in a patient with:
A) eGFR 90 mL/min
B) eGFR 15 mL/min
C) eGFR 70 mL/min
D) Normal creatinine
**Answer: B** ΓÇö An eGFR of 15 reflects severe renal impairment (stage 4ΓÇô5 CKD), significantly reducing
clearance of renally eliminated drugs.
**15.** Which best describes an agonist-antagonist (partial agonist) drug?
A) Full activation of the receptor
B) No receptor binding at all
C) Binds the receptor but produces a submaximal response
D) Always increases the effect of a full agonist
**Answer: C** ΓÇö Partial agonists bind and activate receptors but with lower maximal efficacy than full
agonists, and can blunt effects when combined with a full agonist.
---
## Section 2: Cardiovascular Pharmacology (Q16ΓÇô30)
**16.** A patient on lisinopril develops a dry, persistent cough. The mechanism is:
A) Direct bronchospasm
